# Bill Wickline

> Bill Wickline is a post-ipo debt investor at Bridge Bank backing Health Care. See 3 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bridge Bank](https://shizune.co/investors/profile/bridge-bank)
- Total investments: 3
- Last investment: Aug 2025
- Lead investor: 67%
- Last updated: Aug 2026

Bill Wickline is a post-ipo debt investor at Bridge Bank focused on Health Care and Therapeutics. Bill Wickline is the is the managing director of Bridge Bank's Life Sciences Group.

## Contacts

5 contacts available for Bill Wickline: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/bill-wickline?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| Medical Device | 2 | 67% |
| Medical | 1 | 33% |
| Biotechnology | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 1 | 33% |
| Debt Financing | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Noctrix Health | Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. |  | Debt Financing | Aug 29, 2025 |  |
| Catalyst OrthoScience | Catalyst OrthoScience is an early stage medical device company that is bringing the Catalyst CSR total shoulder to market. The CSR total shoulder is an innovative, streamlined solution that is associated with less stretching of the muscles and ligaments in order to place the implants. It is designed to be a more natural solution with a focus onrapid recovery for the patient. | $20M | Venture - Series Unknown | Sep 10, 2024 |  |
| Cytosorbents | CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surfaceadsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies. | $5M | Post-IPO Debt | Dec 29, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Mutual Capital Partners](https://shizune.co/investors/profile/mutual-capital-partners-funds) — VC Fund, 1 deal together
- [RC Capital](https://shizune.co/investors/profile/river-cities-capital) — VC Fund, 1 deal together

## About Bridge Bank

VC Fund · San Jose, United States

Founded in May 2001, Bridge Bank is the brainchild of some of the most experienced and creative bankers and business people in our community. Our vision was to create a bank that reflects the unique needs of our business community. By combining the resources and services typically associated with larger banks with an unparalleled commitment topersonal service. Bridge Bank offers banking solutions created specifically to help your business grow and prosper.We understand that successful businesses - and the people who run them - have distinctive needs and attributes and our philosophy reflects this understanding. Like our clients, we are committed to being relationship-driven, fast paced and flexible, globally savvy, and technologically advanced.

5 contacts available at Bridge Bank.

| Name | Title | Profile |
| --- | --- | --- |
| Al Williams | EVP & CCO | https://shizune.co/investors/profile/al-williams |
| Bill Wickline | Managing Director Life Sciences Group | — |
| Blake Reid | Senior Director of Tech and Innovation Banking | — |
| Brian Kirkpatrick | VP | — |
| Daniel P. Myers | President & CEO | — |

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Bill Wickline invest in?

Bill Wickline invests primarily in Health Care, Therapeutics and Medical Device startups, most often at Post-IPO Debt and Debt Financing stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bill Wickline?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Bill Wickline last invest?

The most recent investment recorded for Bill Wickline closed in Aug 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co